Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 74, Issue 4, pp 661–665 | Cite as

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

  • Chao-Hua Chiu
  • Teh-Ying Chou
  • Chi-Lu Chiang
  • Chun-Ming Tsai
Review Article

Abstract

There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR mutation testing in LSQC are not consistent among different oncology societies. American Society of Clinical Oncology recommends performing EGFR mutation testing in all patients; European Society for Medical Oncology, College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology, and National Comprehensive Cancer Network suggest for some selected group. EGFR mutation is rarely found in LSQC; however, more importantly, it is not a valid predictive biomarker for EGFR tyrosine kinase inhibitors (EGFR-TKI) in LSQC as it has been shown in LADC. Available data showed that the response rate and progression-free survival in EGFR mutant LSQC patients treated with EGFR-TKI are not better than that observed in patients treated with platinum-doublet chemotherapy in the first-line setting. Therefore, in contrast to advanced LADC, EGFR mutation testing may not be necessarily performed upfront in advanced LSQC because not only the mutation rate is low, but also the predictive value is insufficient. For LSQC patients with known sensitizing-EGFR mutations, both conventional chemotherapy and EGFR-TKI are acceptable frontline treatment options.

Keywords

Epidermal growth factor receptor Nonsmall cell lung cancer Squamous cell carcinoma Tyrosine kinase inhibitor 

References

  1. 1.
    Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128PubMedCrossRefGoogle Scholar
  3. 3.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRefGoogle Scholar
  4. 4.
    Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742PubMedCrossRefGoogle Scholar
  5. 5.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRefGoogle Scholar
  6. 6.
    Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334PubMedCrossRefGoogle Scholar
  7. 7.
    Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222PubMedCrossRefGoogle Scholar
  8. 8.
    Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT et al (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11:3750–3757PubMedCrossRefGoogle Scholar
  9. 9.
    Shukuya T, Takahashi T, Kaira R, Shukuya T, Takahashi T, Kaira R et al (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102:1032–1037PubMedCrossRefGoogle Scholar
  10. 10.
    Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM et al (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121–2127PubMedCrossRefGoogle Scholar
  11. 11.
    Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel Members (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol 22:1507–1519PubMedCrossRefGoogle Scholar
  12. 12.
    Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137:828–860PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology. Non-Small Cell Lung Cancer v.3.2014. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. (Accessed 18 Mar 2014)
  14. 14.
    Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262PubMedCrossRefGoogle Scholar
  15. 15.
    Park K, Goto K (2006) A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 22:561–573PubMedCrossRefGoogle Scholar
  16. 16.
    Hata A, Katakami N, Kunimasa K, Hata A, Katakami N, Kunimasa K et al (2011) Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. Jpn J Clin Oncol 41:1366–1372PubMedCrossRefGoogle Scholar
  17. 17.
    Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH et al (2012) High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 18:1760–1768PubMedCrossRefGoogle Scholar
  18. 18.
    Tseng JS, Yang TY, Chen KC, Hsu KH, Chen HY, Chang GC (2012) Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 77:128–133PubMedCrossRefGoogle Scholar
  19. 19.
    Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF et al (2013) Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol 71:203–208PubMedCrossRefGoogle Scholar
  20. 20.
    Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC et al (2011) Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 72:205–212PubMedCrossRefGoogle Scholar
  21. 21.
    Hata A, Katakami N, Yoshioka H, Kunimasa K, Fujita S, Kaji R et al (2013) How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol 8:89–95PubMedCrossRefGoogle Scholar
  22. 22.
    Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol 21:3909–3917PubMedCrossRefGoogle Scholar
  23. 23.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRefGoogle Scholar
  24. 24.
    Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285PubMedCrossRefGoogle Scholar
  25. 25.
    Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL et al (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167–1176PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Paik PK, Varghese AM, Sima CS, Moreira AL, Ladanyi M, Kris MG et al (2012) Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther 11:2535–2540PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Chao-Hua Chiu
    • 1
    • 2
    • 3
  • Teh-Ying Chou
    • 1
    • 4
  • Chi-Lu Chiang
    • 3
  • Chun-Ming Tsai
    • 2
    • 3
  1. 1.Institute of Clinical MedicineNational Yang-Ming UniversityTaipeiTaiwan
  2. 2.Department of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  3. 3.Division of Thoracic Oncology, Department of Chest MedicineTaipei Veterans General HospitalTaipeiTaiwan
  4. 4.Department of Pathology and Laboratory MedicineTaipei Veterans General HospitalTaipeiTaiwan

Personalised recommendations